Phreesia (PHR) to Release Quarterly Earnings on Wednesday

Phreesia (NYSE:PHR) is anticipated to post its Q2 2027 results after the market closes on Wednesday, September 2nd. Analysts expect the company to announce earnings of $0.0851 per share and revenue of $129.0630 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2027 earning overview page for the latest details on the call scheduled for Wednesday, September 2, 2026 at 5:00 PM ET.

Phreesia Stock Up 0.1%

PHR opened at $12.16 on Tuesday. The company has a market capitalization of $751.61 million, a P/E ratio of 81.07 and a beta of 0.85. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.76 and a quick ratio of 1.76. The firm’s fifty day moving average price is $11.09 and its two-hundred day moving average price is $10.48. Phreesia has a fifty-two week low of $7.77 and a fifty-two week high of $32.74.

Institutional Trading of Phreesia

Large investors have recently added to or reduced their stakes in the company. Invesco Ltd. increased its holdings in shares of Phreesia by 13.1% during the fourth quarter. Invesco Ltd. now owns 82,176 shares of the company’s stock worth $1,390,000 after buying an additional 9,514 shares in the last quarter. State of Tennessee Department of Treasury acquired a new position in shares of Phreesia in the 4th quarter worth approximately $202,000. Mackenzie Financial Corp boosted its holdings in shares of Phreesia by 222.2% in the 4th quarter. Mackenzie Financial Corp now owns 47,882 shares of the company’s stock worth $814,000 after acquiring an additional 33,021 shares in the last quarter. XTX Topco Ltd grew its position in Phreesia by 109.5% during the 4th quarter. XTX Topco Ltd now owns 42,180 shares of the company’s stock worth $714,000 after acquiring an additional 22,046 shares during the last quarter. Finally, VARCOV Co. bought a new stake in Phreesia during the 4th quarter worth approximately $719,000. 92.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PHR. Barclays reaffirmed an “equal weight” rating and set a $10.00 price objective (down from $24.00) on shares of Phreesia in a report on Thursday, May 14th. Truist Financial raised their price target on shares of Phreesia from $11.00 to $12.00 and gave the stock a “hold” rating in a research note on Thursday, May 28th. Weiss Ratings raised Phreesia from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Needham & Company LLC reissued a “buy” rating and issued a $14.00 target price on shares of Phreesia in a report on Monday. Finally, Piper Sandler lowered Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 price target on the stock. in a research note on Thursday, May 28th. Nine research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $16.65.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.